News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Shifting Macro Trends Offer Hope for Biotech Performance Boost

July 6, 2023
By Barbara Ryan
Publication
Article
Pharmaceutical ExecutivePharmaceutical Executive: July 2023
Volume 43
Issue 7

But will Washington’s dealmaking stance upend the momentum?

Barabara Ryan

For the first time since January 2022, the Fed did not raise interest rates at its latest meeting, halting a streak of 10 straight previous hikes and putting at least a pause on the most rapid Fed-induced rise in interest rates in history. That is great news for rate-sensitive biotech stocks. The prolonged and unrelenting string of rate hikes was the No. 1 enemy of biotech valuations, which—as the longest dated of assets—trade inversely with rates. While the market is not wholly convinced that we have seen the last Fed rate hike, it does appear to be looking ahead to a potential for future rate cuts due to a slowdown in inflation, economic growth, rising unemployment, and (potentially) a recession.

This Fed pivot is a major positive shift in the macro climate in favor of biotech. Combined with continued solid momentum in M&A, it has fueled more than a 20% rally off the year-to-date lows as investors rotate back into growth from value. To be expected, capital markets activity has picked up with a healthy flow of follow-on offerings. According to data from SVB Securities, the largest participants, not surprisingly, are the biotech-dedicated investors who have been the biggest winners in M&A trades this year. If sector performance continues to be positive, other life sciences funds will seek out alpha here as will the long-departed generalist investors.

The number of companies in the sector trading below cash is also now declining with the valuation correction, positive datasets, and newfound discipline behind spending, program prioritization, and consolidation.

M&A tailwind remains a reason for optimism

Large pharma is flush with cash and—according to EY’s most recent annual Firepower report—they have more than $1.4 trillion to fund M&A, strategic partnerships, and collaborations. M&A has always been a core pillar of leading companies’ growth strategies, and emerging biotech innovators are their targets. The need has never been greater. In addition, they will face LOEs for products with revenues exceeding $300 billion, beginning in 2025. I expect a strong year of M&A and dealmaking in 2023.

My colleague, Tim Opler of Stifel, says of this year’s M&A activity: “It’s a ‘blistering’ pace on track for $300 billion by year’s end, which could approach an all-time deal record of $328 billion in 2019.” These metrics are according to his firm’s research.

While macro factors may be shifting from headwinds to tailwinds, there are industry-specific storm clouds overhead fueling uncertainty that could threaten short- and long-term fundamentals. Companies and investors will have to monitor these closely.

In a Financial Times article titled “Big Pharma Dealmaking Recovers with $85bn M&A Splurge,” Jamie Smyth talks about M&A trends and the potentially chilling effect of the Federal Trade Commission’s Amgen-Horizon Therapeutics merger suit on biopharmaceutical innovation. Smyth cites Paul Hastings, chief executive of Nkarta, an early-stage biotech company, and an outgoing chair of BIO, the biotech industries’ main lobbying group. Hastings warns “that US antitrust authorities’ tougher stance on pharma/biotech deals risks upending a decades-long business model that underpins innovation. This model attracts investors to biotechs that are pursuing high-risk research in the knowledge that large companies may later buy them and supply the funds needed to complete expensive clinical trials and [commercialize] new drugs.” Smyth also adds that, in the past two decades, small- to mid-sized biotechs have grown in importance to drug development.

The Inflation Reduction Act (IRA), passed in August of 2022, gave Medicare the power to lower prices on certain top-selling drugs that have no competition—starting with 10 medicines in 2026. But the details of the process were left to the US Department of Health and Human Services (HHS) to work out, and it has since released initial guidance and a timeline that will name the first set of drugs up for negotiation by Sept. 1. In addition, the US Chamber of Commerce, Merck, and Bristol Myers Squibb are suing HHS over the IRA, arguing that is unconstitutional.

I believe it’s true that fundamentals for many across our industry are strong, innovation is alive and well, and M&A is—and always has been—a core pillar of the growth strategies for the largest companies; and there is more money to fund it than ever. Biopharma has always been a growth industry, and I don’t believe that has changed or will. There is a lot of money earmarked to be invested behind good data, and patients will be the ultimate beneficiary of the substantive advances our industry continues to deliver.

Download Issue PDF
Articles in this issue

Pharm Exec roundtable
The AI Revolution Has Arrived: Shaping the Next Generation of Pharma Marketing
Kabir Nath
Crossing the Brain Barrier
Matthew Arnold
Biotech’s Survival Story: Companies Bear Down for Lean Years
Celeste Warren
DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles
Doron Aspitz
Harnessing AI for Pharma Sales
Bruce Liu
Tapping New and Improved Drug Innovations in Asia
Jill Wechsler
Drug Shortages Continue to Plague FDA, Manufacturers
EU flag
Contrasting Aims Highlight Pharma Reform Pursuits
Barabara Ryan
Shifting Macro Trends Offer Hope for Biotech Performance Boost
Ira Studin, PhD
‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk
Arda Ural, PhD
Navigating the Recession and Patent Expirations
Meg Rivers
Marketing in the AI Age
Mike Hennessy Jr
AI Heating Up On the Pharma Stage
Pharm Exec July 2023
Pharmaceutical Executive, July 2023 Issue (PDF)
Recent Videos
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Fred Aslan
Related Content

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Don Tracy, Associate Editor
May 20th 2025
Article

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.


BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

Don Tracy, Associate Editor
May 19th 2025
Article

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.


Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Novo Nordisk, Septerna Enter Global Collaboration to Develop Cardiometabolic Medicines

Novo Nordisk, Septerna Enter Global Collaboration to Develop Cardiometabolic Medicines

Don Tracy, Associate Editor
May 15th 2025
Article

The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines.


GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease

GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease

Don Tracy, Associate Editor
May 14th 2025
Article

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.


GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

Don Tracy, Associate Editor
May 13th 2025
Article

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

Related Content

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Pfizer, 3SBio Forge Licensing Pact for SSGJ-707 to Target Lung, Colorectal, and Gynecologic Cancers

Don Tracy, Associate Editor
May 20th 2025
Article

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.


BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition

Don Tracy, Associate Editor
May 19th 2025
Article

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency.


Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Novo Nordisk, Septerna Enter Global Collaboration to Develop Cardiometabolic Medicines

Novo Nordisk, Septerna Enter Global Collaboration to Develop Cardiometabolic Medicines

Don Tracy, Associate Editor
May 15th 2025
Article

The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines.


GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease

GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease

Don Tracy, Associate Editor
May 14th 2025
Article

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.


GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

Don Tracy, Associate Editor
May 13th 2025
Article

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.